PG
SAGE

Pendal Group’s Sage Therapeutics SAGE Stock Holding History

Pendal Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$332K Buy
+8,702
New +$332K ﹤0.01% 424

Other funds holding SAGE

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pendal Group's SAGE Position: Q4 2022 in Review

Pendal Group opened a new position in Sage Therapeutics (SAGE) in Q4 2022: 8,702 shares worth $332K. The stake represents ﹤0.01% of the portfolio and ranks #424 among its holdings.

206 funds tracked by Wall St. Rank hold SAGE as of Q4 2022.

  • Pendal Group held 8,702 shares of Sage Therapeutics worth $332K as of Q4 2022.
  • Sage Therapeutics was a new Pendal Group position in Q4 2022.
  • Sage Therapeutics made up ﹤0.01% of Pendal Group's portfolio in Q4 2022, its #424 holding.
  • 206 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.